Suppr超能文献

联合粪便免疫化学检测和血液检测结果进行结直肠癌风险分层:一项纳入 16604 例首诊于基层医疗的连续队列研究。

Combining faecal immunochemical testing with blood test results for colorectal cancer risk stratification: a consecutive cohort of 16,604 patients presenting to primary care.

机构信息

Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Oxford, OX2 6GG, UK.

Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation, Oxford, UK.

出版信息

BMC Med. 2022 Mar 15;20(1):116. doi: 10.1186/s12916-022-02272-w.

Abstract

BACKGROUND

Faecal immunochemical tests (FITs) are used to triage primary care patients with symptoms that could be caused by colorectal cancer for referral to colonoscopy. The aim of this study was to determine whether combining FIT with routine blood test results could improve the performance of FIT in the primary care setting.

METHODS

Results of all consecutive FITs requested by primary care providers between March 2017 and December 2020 were retrieved from the Oxford University Hospitals NHS Foundation Trust. Demographic factors (age, sex), reason for referral, and results of blood tests within 90 days were also retrieved. Patients were followed up for incident colorectal cancer in linked hospital records. The sensitivity, specificity, positive and negative predictive values of FIT alone, FIT paired with blood test results, and several multivariable FIT models, were compared.

RESULTS

One hundred thirty-nine colorectal cancers were diagnosed (0.8%). Sensitivity and specificity of FIT alone at a threshold of 10 μg Hb/g were 92.1 and 91.5% respectively. Compared to FIT alone, blood test results did not improve the performance of FIT. Pairing blood test results with FIT increased specificity but decreased sensitivity. Multivariable models including blood tests performed similarly to FIT alone.

CONCLUSIONS

FIT is a highly sensitive tool for identifying higher risk individuals presenting to primary care with lower risk symptoms. Combining blood test results with FIT does not appear to lead to better discrimination for colorectal cancer than using FIT alone.

摘要

背景

粪便免疫化学检测(FIT)用于对可能因结直肠癌引起症状的初级保健患者进行分诊,以转诊行结肠镜检查。本研究旨在确定 FIT 与常规血液检查结果联合应用是否可以提高 FIT 在初级保健环境中的性能。

方法

从牛津大学医院 NHS 基金会信托基金中检索了 2017 年 3 月至 2020 年 12 月期间所有由初级保健提供者请求的连续 FIT 结果。还检索了人口统计学因素(年龄、性别)、转诊原因以及 90 天内的血液检查结果。通过链接的医院记录对患者进行新发结直肠癌的随访。比较了单独使用 FIT、FIT 与血液检查结果配对以及几个多变量 FIT 模型的敏感性、特异性、阳性预测值和阴性预测值。

结果

诊断出 139 例结直肠癌(0.8%)。FIT 单独在阈值为 10 μg Hb/g 时的敏感性和特异性分别为 92.1%和 91.5%。与单独使用 FIT 相比,血液检查结果并未改善 FIT 的性能。将血液检查结果与 FIT 配对虽然提高了特异性,但降低了敏感性。包含血液检查的多变量模型与单独使用 FIT 表现相似。

结论

FIT 是一种高度敏感的工具,可用于识别在初级保健就诊时出现低风险症状但具有更高风险的个体。与单独使用 FIT 相比,将血液检查结果与 FIT 联合使用似乎并不能提高对结直肠癌的鉴别能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6329/8922811/52cf03e09777/12916_2022_2272_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验